93Z.F MARINOMED BIOTECH AG INH.
- Market cap
- EUR 7.52M
- P/E
- 0.4x
- P/B
- 605.08x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 93Z.F undervalued?
Graham numberThe Graham number of MARINOMED BIOTECH AG INH. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MARINOMED BIOTECH AG INH. fundamental analysis
No fundamental analysis for MARINOMED BIOTECH AG INH. yet.
MARINOMED BIOTECH AG INH. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MARINOMED BIOTECH AG INH.
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation developmen…
Full company profileMARINOMED BIOTECH AG INH. financial statements
MARINOMED BIOTECH AG INH. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 11.6M | 11.3M | 9.06M | 4.75M | 7.69M |
| Gross Profit | 1.42M | 2.14M | 981K | 980K | 6.27M |
| Operating Income | -4.13M | -4.87M | -5.00M | -6.95M | -245K |
| EBITDA | - | -3.21M | -4.53M | -7.18M | 19.0M |
| Net Income | -5.89M | -6.40M | -6.37M | -15.4M | 18.0M |
| EPS | -3.98 | -4.25 | -4.18 | -8.67 | 9.76 |
| Balance Sheet | |||||
| Total Assets | 21.3M | 22.3M | 12.4M | 8.18M | 5.95M |
| Total Liabilities | 21.1M | 26.4M | 25.0M | 34.3M | 13.0M |
| Shareholders' Equity | 191K | -4.16M | -12.6M | -26.2M | -7.05M |
| Cash & Short-term Investments | 5.80M | 8.18M | 2.56M | 1.71M | 952K |
| Cash Flow | |||||
| Operating Cash Flow | -4.87M | -5.20M | -3.70M | -2.40M | -1.10M |
| Capital Expenditure | 919K | 228K | 129K | 0.00 | 0.00 |
| Free Cash Flow | -5.79M | -5.43M | -3.70M | -2.40M | -1.10M |
| Ratios | |||||
| ROE | -3,078.0% | - | - | - | - |
| ROA | -27.6% | -28.7% | -51.5% | -188.4% | 302.8% |
| Net Profit Margin | -50.7% | -56.7% | -70.3% | -324.8% | 234.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MARINOMED BIOTECH AG INH. dividends
MARINOMED BIOTECH AG INH. has not paid dividends in the last 5 fiscal years.
Who owns MARINOMED BIOTECH AG INH.
- Insiders 23.83%
- Institutions 14.81%
- Public & others 61.36%
- Shares outstanding 2.00M
- Free float 1.37M
MARINOMED BIOTECH AG INH. company profile
- Company name
- MARINOMED BIOTECH AG INH.
- Ticker
- 93Z.F
- ISIN
- ATMARINOMED6
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 32
- Fiscal year end
- December
- Address
- Hovengasse 25, Korneuburg, Austria, 2100
- Phone
- 43 2262 90300
- Website
- marinomed.com
About MARINOMED BIOTECH AG INH.
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
MARINOMED BIOTECH AG INH. management
4- Mr. Andreas Grassauer Ph.D.Co-Founder, Chairman of Management Board & CEO · born 1969
- Ms. Eva Prieschl-Grassauer Ph.D.Co-Founder, Vice Chairwoman of Management Board & Chief Scientific Officer · born 1968
- Ms. Gabriele RamAuthorized Signatory, Head of Finance & Member of Management Board
- Ms. Stephanie KniepHead of Investor Relations